Share Prices & Company Research

Stockbroking

Dechra Pharmaceuticals

Current Price 2828.00p Bid 2798.00p Ask 2800.00p Change -1.34%
Last Updated: 23/02/2020 07:08. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

Dechra Pharmaceuticals plc is an international specialist veterinary pharmaceuticals and relates products business. Our expertise is in the development, manufacture and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.

Financial Highlights Year Ended 30/06/2019

Turnover
£481.80m
Operating Profit
£39.00m
Dividend Yield
1.12
Dividend Per Share
31.60
Dividend Cover
0.95
P/E Ratio
93.86

Key Personnel

Ian David Page
Chief Executive
Paul Nicholas Sandland
Chief Financial Officer
Anthony Gerard Griffin
Executive Director
William Anthony Rice
Non-Executive Chairman
Dr Lawson Macartney
Non-Executive Director
Ishbel Jean Stewart Macpherson
Non-Executive Director
Julian Spenser Heslop
Non-Executive Director
Lisa Jane Bright
Non-Executive Director

Stock Details

EPIC
DPH
ISIN
GB0009633180
Shares in Issue
102,866,886
Market cap
£2,911.13m

Analyst Views (3)

Strong Buy
 
33.33%
Buy
 
0.00%
Hold
 
66.67%
Sell
 
0.00%
Strong Sell
 
0.00%
The above information represents a selection of the views published in the last 120 days by analysts. It is subject to change without notice and doesn't reflect view held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
2800.00p
Bid Price
2798.00p
Ask Price
2800.00p
Volume
168743
Change Today
-38.00p
% Change Today
-1.34%
Open
2866.00p
Previous Close
2800.00p
Intraday High
2866.00p
Intraday Low
2794.00p
52 Week High
3090.00p
52 Week Low
2336.00p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

Dechra Pharmaceuticals Intra-day Chart

Dechra Pharmaceuticals News

News in this section is provided by AJ Bell

Broker Forecast - Jefferies International issues a broker note on Dechra Pharmaceuticals PLC 21 Jan 2020 | 10:10 Dechra Pharmaceuticals says annual performance to be more second half weighted 16 Jan 2020 | 08:29 FTSE closes in the red as Iran tensions escalation spooks investors, sparking oil and gold rallies 06 Jan 2020 | 17:01 Broker Forecast - JP Morgan Cazenove issues a broker note on Dechra Pharmaceuticals PLC 06 Jan 2020 | 11:10 Dechra acquires rights to dog inflammation product for $135m 06 Jan 2020 | 07:34 Broker Forecast - HSBC issues a broker note on Dechra Pharmaceuticals PLC 02 Dec 2019 | 10:10 Dechra appoints Paul Sandland as permanent CFO 30 Oct 2019 | 07:24 Dechra Pharmaceuticals 'confident' about prospect as efforts to resolve supply issues continue 18 Oct 2019 | 08:01 Director Deals - Dechra Pharmaceuticals PLC (DPH) 23 Sep 2019 | 17:15 Director Deals - Dechra Pharmaceuticals PLC (DPH) 23 Sep 2019 | 17:15 Director Deals - Dechra Pharmaceuticals PLC (DPH) 23 Sep 2019 | 17:15 Director Deals - Dechra Pharmaceuticals PLC (DPH) 18 Sep 2019 | 10:50 Director Deals - Dechra Pharmaceuticals PLC (DPH) 18 Sep 2019 | 10:50 Broker Forecast - JP Morgan Cazenove issues a broker note on Dechra Pharmaceuticals PLC 04 Sep 2019 | 11:30 UK stocks hold on to gains at close 02 Sep 2019 | 16:22 UK stocks add to gains at midday 02 Sep 2019 | 11:50 UK stocks open 0.6% higher as Brexit drama intensifies 02 Sep 2019 | 09:03 Dechra Pharmaceutical profit ticks lower despite 'exceptional' growth in US 02 Sep 2019 | 07:48 Dechra acquires Ampharmco for $30m 29 Aug 2019 | 09:46 Dechra signs licnesing agreement with Akston Biosciences Corporation for dog diabetes drug 02 Aug 2019 | 09:26 FTSE claws back some ground by lunchtime 09 Jul 2019 | 12:07 Dechra Pharmaceutical revenues lifted by 'good' market penetration, synergies from Le Vet acquisition 09 Jul 2019 | 07:44 Dechra acquires further 15% stake in Medical Ethics for AUD$13.5m 05 Jul 2019 | 08:02 FTSE rises in spite of strong sterling after robust US open 03 Apr 2019 | 16:40 Stronger sterling stalls FTSE amid potential Brexit progress 03 Apr 2019 | 09:05 Dechra's Richard Cotton steps down as CFO for 'personal reasons' 03 Apr 2019 | 07:44 Broker Forecast - Jefferies International issues a broker note on Dechra Pharmaceuticals PLC 25 Mar 2019 | 12:50 Broker Forecast - JP Morgan Cazenove issues a broker note on Dechra Pharmaceuticals PLC 25 Mar 2019 | 09:10 Broker Forecast - HSBC issues a broker note on Dechra Pharmaceuticals PLC 11 Mar 2019 | 11:40 Dechra Pharmaceuticals underlying profit rises, led by North America 25 Feb 2019 | 16:25

Assets (£m)

Data has been provided by AJ Bell

Reporting Date
30 Jun 2019
30 Jun 2018
Tangible Assets
58.4
45.3
Intangible Assets & Goodwill
687.0
709.8
Investments & Other Non-Current Assets
11.0
14.3
Total Non-Current Assets
756.4
769.4
Inventory
104.0
86.6
Trade & Receivables
99.9
81.6
Cash & Receivables
80.3
79.7
Other Current Assets & Assets Held for Resale
7.9
0.0
Total Assets
1,048.5
1,017.3

Liabilities (£m)

Data has been provided by AJ Bell

Reporting Date
30 Jun 2019
30 Jun 2018
Short Term Liabilities
118.1
91.6
Long Term Liabilities
421.3
420.7
Other Liabilities / Pension etc
0.0
0.0
Total Liabilities
539.4
512.3

Net Assets (£m)

Data has been provided by AJ Bell

Reporting Date
30 Jun 2019
30 Jun 2018
Net Assets
509.1
505.0

Equity (£m)

Data has been provided by AJ Bell

Reporting Date
30 Jun 2019
30 Jun 2018
Share Capital
1.0
1.0
Minority Interests
0.0
0.0
Retained Earnings
124.2
125.5
Share Premium Account
277.9
359.3
Other Equity
106.0
19.2
Total Equity
509.1
505.0

Cashflow (£m)

Data has been provided by AJ Bell

Reporting Date
30 Jun 2019
30 Jun 2018
Cashflow from Operating Activities
81.8
64.0
Cashflow Before Financing
19.9
-177.7
Increase / Decrease in Cash
-0.2
16.1

Income (£m)

Data has been provided by AJ Bell

Reporting Date
30 Jun 2019
30 Jun 2018
Turnover
481.8
407.1
Cost of Sales
208.7
184.7
Gross Profit
273.1
222.4
Operating Profit
39.0
34.1
Pre-Tax Profit
27.8
28.9
Profit / Loss for the Year
30.9
36.1

Dividend History

Data has been provided by AJ Bell

Period
Ex-Dividend Date
Payment Date
H2 Dividend
24 Oct 2019
15 Nov 2019
H1 Dividend
07 Mar 2019
08 Apr 2019
H2 Dividend
25 Oct 2018
16 Nov 2018
H1 Dividend
08 Mar 2018
06 Apr 2018
H2 Dividend
26 Oct 2017
17 Nov 2017
H1 Dividend
09 Mar 2017
07 Apr 2017
H2 Dividend
27 Oct 2016
18 Nov 2016
H1 Dividend
10 Mar 2016
06 Apr 2016
H2 Dividend
29 Oct 2015
20 Nov 2015
H1 Dividend
12 Mar 2015
07 Apr 2015
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.